on March 6, 2018 Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, reported that Joshua H. Bilenker, M.D., chief executive officer, will present a corporate overview at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:00 a.m. ET (Press release, Loxo Oncology, MAR 6, 2018, View Source [SID1234524454]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live broadcast of the presentation will be available at View Source An archived replay of the presentation will be available on the company’s website for 30 days following the presentation.

On March 6, 2018 Acorda Therapeutics, Inc. (Nasdaq:ACOR) reported that Ron Cohen, M.D., Acorda’s President and CEO, will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13 at 10:00am EST (Press release, Acorda Therapeutics, MAR 6, 2018, View Source [SID1234524405]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation can be accessed under "Investor Events" in the Investor section of the Acorda website at www.acorda.com, or you may use the link:

http://wsw.com/webcast/cowen46/acor/

On March 6, 2018 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, reported that its president and chief executive officer, Roger J. Lias, Ph.D., will deliver a corporate presentation at the 30th Annual ROTH Conference (Press release, Avid Bioservices, MAR 6, 2018, View Source [SID1234524436]). The conference is being held March 11-14, 2018 at the Ritz-Carlton Laguna Niguel in Dana Point, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of this presentation are as follows:

30th Annual ROTH Conference
Time/Date: 2:00 p.m. PT on Tuesday, March 13, 2018
Location: Ritz-Carlton Laguna Niguel, Dana Point, CA
Room: Yellow Salon 6
Avid’s presentation at the ROTH conference will be webcast live and available for replay at: View Source

On March 6, 2018 Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies*, reported that it will present at the Cowen and Company 38th Annual Healthcare Conference on Tuesday, March 13, 2018 at 8:00 ET (2:00 PM CET) (Press release, Molecular Partners, MAR 6, 2018, View Source [SID1234524455]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, followed by a breakout session, will be hosted by Dr. Patrick Amstutz, CEO of Molecular Partners and Dr. Michael Stumpp, CSO of the company.

The presentation will be webcast live and can be accessed on the day via this link. A copy of the presentation handout as well as a replay of the webcast will be made available on the company’s website www.molecularpartners.com under the Investors section. The replay will be available for 90 days following the presentation.

Rigel has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Rigel, 2018, MAR 6, 2018, View Source [SID1234524473]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!